After 1 year, WW Clinic members prescribed weight management medications who added the WW Points program lost 8% more weight than WW Clinic members who did not.** **Based on observational study of 1400 Clinic members who added the WW Points program to their membership and lost -17.7% body weight on average, compared to 2606 Clinic members who did not start a WW membership during this timeframe and lost -16.4% body weight on average
This establishes a baseline of minimal symptoms
Gastrointestinal adverse events occurred in 53.1% of the semaglutide 7.2 mg group, 51.5% of the semaglutide 2.4 mg group and 25.5% of the placebo group, according to the researchers
COMPARISON WITH RESMETIROM AND THE CASE FOR COMBINATION STRATEGIES Resmetirom, an orally active, liver-directed thyroid hormone receptor- (THR-) agonist, has recently shown positive phase 3 trial results in patients with MASH and F1-F3 fibrosis, improving both MASH resolution and fibrosis compared with placebo
The exact mechanisms behind this effect are not fully understood, but it is believed that semaglutide helps regulate appetite and satiety, as well as potentially increasing energy expenditure
The morning after, prioritize electrolyte-rich fluids before coffee or food
